Viewing StudyNCT04837716



Ignite Creation Date: 2024-05-06 @ 4:00 PM
Last Modification Date: 2024-10-26 @ 2:01 PM
Study NCT ID: NCT04837716
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-02-23
First Post: 2021-04-05

Brief Title: Ensartinib Carboplatin Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center

Conditions & Keywords Data

Conditions:
Name
Stage IVB Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Keywords: